Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma

International Surgery

Volumn 92, Issue 4, 2007, Pages 202-208

  Takakura, Satoshi ^a   Saito, Motoaki ^a   Ueda, Kazu ^a   Motegi, Makoto ^a   Takao, Miho ^a   Yamada, Kyosuke ^a   Okamoto, Aikou ^a   Niimi, Shigeki ^a   Sasaki, Hiroshi ^a   Tanaka, Tadao ^a   Ochiai, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; CPT 11; Ovarian clear cell adenocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DRUG DERIVATIVE; IRINOTECAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; DISEASE COURSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36549079557     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Serov SF, Scully RE, Jobin LH. Histologic typing of ovarian tumors. In: International Histological Classification of Tumors, no. 9. Geneva, Switzerland: World Health Organization, 1973: 37-42
2. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88: 2584-2589
3. Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Hirata J et al. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 2000;7:327-331
4. Ochiai K, Sasaki H, Terashima Y, Fukushima M. Prognostic factor analysis and treatment results of ovarian cancer in Japan. Int J Technol Assess Health Care 1994;10:406-425
5. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989;7:457-465
6. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-417
7. Rubin SC, Wong GY, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993;82:143-147
8. Wakisaka T, Sou S. A case of recurrent ovarian cancer successfully treated with etoposide. Gan To Kagaku Ryoho 1988;15:1795-1798
9. Takeshima N, Hirai Y, Shimizu Y, Umezawa S, Kato T, Yamawaki T et al. A report on a case with recurrent ovarian clear cell adenocarcinoma (peritoneal dissemination) who exhibited a remarkable response to CPT-11. J Jpn Soc Cancer Ther 1995;30:705-711
10. Umezawa S, Shimizu Y, Takeshima N, Hasumi K. Chemotherapy for ovarian clear cell adenocarcinoma with irinotecan hydrochloride and mitomycin C. Int J Clin Oncol 1996;1:157-162
11. Sugiyama T, Yakushiji M, Nishida T, Ushijima K, Okura N, Kigawa J et al. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 1998;128:211-218
12. Adachi S, Ogasawara T, Yamasaki N, Shibahara H, Kanazawa R, Tsuji Y et al. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol 1999;29: 434-437
13. Sugiyama T, Yakushiji M, Kamura T, Ikeda M, Umesaki N, Hasegawa K et al. Japan CPT-11 Study Group. Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology 2002;63:16-22
14. Kigawa T, Takahashi M, Minagawa Y, Oishi T, Sugiyama T, Yakushiji M et al. Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer. Int J Cancer 1999;84:521-524
15. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70:255-258
16. Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 2004;94:197-203
17. Enomoto T, Kuragaki C, Yamasaki M, Sugita N, Otsuki Y, Ikegami H et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 2003;22:447